

WP 6 In vivo genotoxicity



Valérie Fessard Anses Fougères France

valerie.fessard@anses.fr

NANOGENOTOX – Final conference – 22 February 2013





WP6 partners

9 partnersfrom 7 countries

National Institute for Public Health and the Environment (The Netherlands)	RIVM	rivm
National Research Centre for the Working Environment (Denmark)	NRCWE	STREAM REAL RELATION CONTRA
The Nofer institute of Occupational Medicine (Poland)	NIOM	Diversity of the transmission of transmission of the transmission of transmission
Institut Pasteur of Lille (France)	IPL	Pasteur de Lille
National Health Institute Doutor Ricardo Jorge (Portugal)	INSA	() ()
Institut national de recherche et de sécurité (France)	INRS	TITS
Roumen Tsanev Institute of Molecular Biology Academy of Sciences (Bulgaria)	IMB- BAS	Sealing of Sealing of Seal
Finnish Institute of Occupational Health (Finland)	FIOH	Finnish Institute of Occupational Health
French Agency for Food, Environmental and Occupational Health Safety (France)	ANSES	anses 🗘

NANOGENOTOX – Final Conference – 22 February 2013






Aims

Determine the *in vivo* genotoxicity of MNs (TiO2, SAS and CNT)

Comparison in vitro/in vivo /(Physic-chem)








Methodology

Genotoxicity:



- 3 complementary tests
 - Comet assay (early DNA damage) on rats
 - Micronucleus assay (chromosome and genome mutations) on rats
 - Mutation Lac Z assay (gene mutations) on mice


Comet and micronucleus tests coupled to reduce the number of animals for ethical point of view







Methodology

- Inflammation and oxidative stress:
 - Broncho alveolar cells count
 - Histology



 Modified comet assay with FpG enzyme for selective detection of oxidative lesions; some lipid peroxidation measurements in plasma





NANOGENOTOX – Final Conference – 22 February 2013





Methodology


2 routes of exposure: gavage and instillation,
 some iv data also (NM102, 103, 104 and 203)

- 4 MNs per type (4 SAS, 4 TiO₂ and 4 CNT)
- Chemical positive control






Various organs both in site of contact and systemic ones













Methodology

- Training and trials organized before the assays with MNs
 - For the micronucleus assays on bone marrow and colon
 - About positive control: which unique chemical? which dose? What about a nanosized one?
 - MMS and CPA
 - Carbon black





Gavage

		Comet assay						MNA				
		Lung	BAL	Blood	Liver	Spleen	Bone marrow	Intestine	Colon	Kidney	bone marrow	MNA colon
	MMS	++	++	++	++	++	++	++	++	++	+	+
	СРА	nd	nd	-	-	-	+	-	+	-	toxic	+
CB (µg/kg)	250	nd	nd	-	-	-	-	-	+	-	-	-
	1250	nd	nd	-	-	-	-	-	+	-	-	+
	2500	nd	nd	-	-	-	-	-	+	-	-	+

MMS 100 mg/kg (x3) except for BAL and lung (25 mg/kg x3) CPA 40 mg/kg (X3)

MMS selected for chemical positive control Carbon Black not included





Methodology

Doses selected (from the dispersion protocol and the WP7 results):

- TiO2: 4.6, 2.3 and 1.15 mg/kg (x3) instillation

26, 13.5, 6.5 mg/kg (x3) gavage

2.3 mg/animal (X5) NM103 and 104 intravenous (WP7)

10 and 15 mg/kg (x2) NM102 intravenous (LacZ)

- SAS: 12, 6 and 3 mg/kg (x3) instillation

20, 10 and 5 mg/kg (x3) gavage and NM203 intravenous

- **CNT**: 51.2, 25.6 and 12.8 mg/kg (x 3) for gavage except for NM400 (12.8, 6.4, 3.2 mg/kg (x3))

0.4, 0.2 and 0.1 mg/kg (x3) for instillation except for NM402 (1.6, 0.8 and 0.4 mg/kg (x3))





Results

TiO2

- Comet assay:

Most MNs inducing **no DNA damage** irrespective of the organ except after instillation NM105 in BAL and after gavage in spleen, intestine (NM103), colon (NM102 and 104) and bone marrow (NM104)


Genotoxic effect observed in organs **depending on the route** (BAL for instillation; spleen and GI tract for gavage)



Comet assay: instillation and gavage with TiO2

Grant agreement number 2009 21 01

NANOGENTOX




NANOGENOTOX – Final Conference – 22 February 2013



Comet assay: instillation and gavage with TiO2

Grant agreement number 2009 21 01

NANOGENTOX



NANOGENOTOX – Final Conference – 22 February 2013





Results

TiO2

-MN assays:

No mutagenicity in bone marrow

after instillation, gavage or iv

- Lac Z (iv administration with NM102):

no genotoxicity in spleen and liver (comet) **no clastogenicity** in blood (micronucleus) **no mutagenicity** in liver (lac Z mutation)





Lac Z assay iv with NM102

Assay	Peripheral Blood	Liver	Spleen
Micronucleus*	NEGATIVE	Not done	Not done
Comet**	Not done	NEGATIVE	NEGATIVE
LacZ mutation***	Not done	NEGATIVE	Under analysis
TEM	Not done	Under analysis	Not done
Histopathology	Not done	To be done	Not done

* Chi-square test; positive control was increased (P<0.0001)
** Kruskall-Wallis test; positive control was increased in liver (P=0.008)
*** Kruskall-Wallis test; positive control was increased in liver (P=0.032)

NANOGENOTOX – Final Conference – 22 February 2013





Results

SAS

- Comet assay:

No DNA damage


irrespective of the organ and the route of administration (instillation, gavage and iv for NM203)



Comet assay: instillation, gavage and IV with SAS

Grant agreement number 2009 21 01

NANOGEN TOX




NANOGENOTOX – Final Conference – 22 February 2013



Comet assay: instillation, gavage and IV with SAS

Grant agreement number 2009 21 01

NANOGEN-TOX



NANOGENOTOX – Final Conference – 22 February 2013







SAS

- Micronucleus assay:

- Bone marrow:

no induction of micronuclei irrespective of the route of administration except after iv with NM 203 at the high dose (but no dose response, small increase as well as animal toxicity)

- Colon:


increase of micronuclei formation for NM202 and 203 only at the lowest dose



Colon micronucleus assay with SAS

Grant agreement number 2009 21 01

NANOGENTOX



NANOGENOTOX – Final Conference – 22 February 2013

MMS: 2 first doses 100 mg/kg, the 3rd 80 mg/kg * For p \leq 0.05; ** for p \leq 0.01 and *** for p \leq 0.001 with χ^2 test with Yate's correction





Results

CNT

- Comet assay:

Some genotoxicity induced in various organs


After gavage NM401 in liver and kidney After instillation, depending on the NP, in kidney, spleen, lung and BAL



Comet assay: instillation and gavage with CNT

Grant agreement number 2009 21 01

NANOGENTOX




NANOGENOTOX – Final Conference – 22 February 2013





NANOGENTOX



NANOGENOTOX – Final Conference – 22 February 2013





Results

CNT

-Micronucleus assay:

- Bone marrow:

no mutagenicity irrespective of the route of administration

- Colon:

no mutagenicity with NRCWE 006






Intra and inter laboratory variabilities

Grant agreement number 2009 21 01

Results



Variabilities due to the assay leading in few cases to invalidated data and inconclusive results

Provide some criteria of acceptability for the non-OECD tests (EFSA 2012)





Results

□ Not much effect from oxidative damage due to MN exposure when it had been measured by the modified Fpg comet assay

Some toxicity observed:

- death after iv exposure with NM203 (2/5; 20 mg/kg)
- diarrhea after gavage with NM105 (3/5; 26 mg/kg)

Some data still expected (especially micronucleus on colon)

Comparison with *in vitro* and phys-chem to be performed





Conclusions

Most data indicating no genotoxicity

□ However some genotoxic effect observed in few organs that need to be confirmed, few dose response

□ Apparently, within the same family, the toxic effect varies according to the MN (genotoxicity but also toxic injuries)

- Negative results with the OECD guideline 474 on bone marrow (except after iv with NM 203 at the high dose)
- □ Use of non-OECD tests which would require to set up some criteria of acceptability because some variability from lab to lab highlighted
 - Comparison with the other WP results





WP6 comments of external experts

Laetitia Gonzalez, Micheline Kirsch-Volders Vrije Universiteit Brussel

NANOGENOTOX – Final conference – 22 February 2013





Strengths

- Comparison of 3 exposure routes (it instillation, iv injection, gavage)
- Use of two complementary assays
 - Comet assay
 - MN assay
- Collaborative experiments with clear protocols
- Training
- Critical assessment of the results

NANOGENOTOX – Final Conference – 22 February 2013

Weaknesses

- Tissue type choice after specific route of exposure (e.g. bone marrow after gavage or it instillation)
- Acceptability criteria and historical controls





Recommendations for future research

- Focus on relevant organs depending on route of exposure
 - Colon after gavage
 - Bone marrow after iv injection (OECD validated)
 - Epithelial lung cells after it instillation
- Validation of in vivo genotoxicity assays in colon and lung cells

